News - Boehringer Ingelheim, Anti-virals

Filter

Popular Filters

Boehringer Ingelheim presents new data for HCV/HIV candidate faldaprevir

Boehringer Ingelheim presents new data for HCV/HIV candidate faldaprevir

06-03-2014

German family-owned pharma major Boehringer Ingelheim announced positive results from STARTVerso 4 in…

Anti-viralsBoehringer IngelheimfaldaprevirPharmaceuticalRegulationResearch

Boehringer Ingelheim’s faldaprevir effective even in hep C patients with common drug-resistant viral variant

Boehringer Ingelheim’s faldaprevir effective even in hep C patients with common drug-resistant viral variant

17-12-2013

New data show that family-owned German drug major Boehringer Ingelheim’s second-generation protease…

Anti-viralsBoehringer IngelheimfaldaprevirPharmaceuticalResearch

EMA accelerated assessment for Boehringer hep C candidate faldaprevir

EMA accelerated assessment for Boehringer hep C candidate faldaprevir

27-11-2013

Family-owned German drug major Boehringer Ingelheim says that its application for European marketing…

Anti-viralsBoehringer IngelheimEuropefaldaprevirPharmaceuticalRegulation

AASLD meeting highlights: Gilead’s sofosbuvir, Janssen’s simeprevir and Boehringer’s faldaprevir

03-11-2013

Among research results released at this week at the 64th Annual Meeting of the American Association for…

Anti-viralsBiotechnologyBoehringer IngelheimfaldaprevirGilead SciencesJanssenJohnson & JohnsonPharmaceuticalResearchsimeprevirsofosbuvir

Boehringer Ingelheim links with Presidio on interferon-free hepatitis C treatment regimens

10-09-2013

The US subsidiary of German family-owned drug major Boehringer Ingelheim says it has completed patient…

Anti-viralsBoehringer IngelheimdeleobuvirfaldaprevirPharmaceuticalPPI-668Presidio PharmaceuticalsResearch

Boehringer Ingelheim's all-oral interferon-free combination achieved 95% viral cure rates in genotype-1b hepatitis C

14-06-2013

New data from German family-owned drug major Boehringer Ingelheim's interferon-free SOUND-C3, presented…

Anti-viralsBoehringer IngelheimdeleobuvirfaldaprevirPharmaceuticalResearch

Gilead gains FDA priority review for hep C candidate sofosbuvir; new data on Boehringer's faldaprevir

10-06-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) revealed on Friday (June 7) that the US Food and Drug…

Anti-viralsAsia-PacificBiotechnologyBoehringer IngelheimfaldaprevirGilead SciencesNorth AmericaPharmaceuticalRegulationResearchsofosbuvir

Presidio Pharma inks deal with Boehringer Ingelheim for hep C combo

14-03-2013

Privately-held USA-based Presidio Pharmaceuticals has entered into a non-exclusive collaboration with…

Anti-viralsBI207127Boehringer IngelheimfaldaprevirPharmaceuticalPPI-668Presidio PharmaceuticalsResearch

Interim results indicate potent activity of Boehringer's faldaprevir in HCV/HIV co-infected patients

05-03-2013

Patients with hepatitis C virus(HCV)/HIV co-infection have a high unmet clinical need. The encouraging…

Anti-viralsBoehringer IngelheimfaldaprevirPharmaceuticalResearch

Breckenridge in generic Viramune deal with Zhejiang Huahai Pharma

07-05-2012

Privately-held US generic drugmaker Breckenridge Pharmaceutical that it has finalized its agreement with…

Anti-viralsAsia-PacificBoehringer IngelheimBreckenridge PharmaceuticalsGenericsMarkets & MarketingNevirapineNorth AmericaPatentsViramuneZhejiang Huahai Pharma

Boehringer license novel HIV non-catalytic integrase inhibitors to Gilead

07-10-2011

Two of the big names in HIV/AIDS drug research and marketing, the USA’s Gilead Sciences (Nasdaq:…

Anti-viralsBoehringer IngelheimGilead SciencesLicensingPharmaceutical

Boehringer once-daily AIDS drug Viramune cleared in EU

21-09-2011

Independent German drug major Boehringer Ingelheim says that once-daily Viramune (nevirapine) prolonged-release…

Anti-viralsBoehringer IngelheimEuropePharmaceuticalRegulationViramune

Back to top